Andrea Navarria

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Richard E. Pratley, Vanita R. Aroda, Ildiko Lingvay et al. · The Lancet Diabetes & Endocrinology · 2018 · 764 citations

Medicine, Pharmacology, Pharmacotherapy +13

Scopolamine Rapidly Increases Mammalian Target of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses

Bhavya Voleti, Andrea Navarria, Rong-Jian Liu et al. · Biological Psychiatry · 2013 · 262 citations · Full text

Medicine, Neuroscience, Pharmacology +16

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

Yuichiro Yamada, Hideki Katagiri, Yoshiyuki Hamamoto et al. · The Lancet Diabetes & Endocrinology · 2020 · 223 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto et al. · The Lancet Diabetes & Endocrinology · 2020 · 203 citations

Medicine, Pharmacology, Pharmacotherapy +15

Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors

Andrea Navarria, Eric S. Wohleb, Bhavya Voleti et al. · Neurobiology of Disease · 2015 · 117 citations · Full text

Medicine, Neuroscience, Pharmacology +16